Christine Sam, MD

home / authors / christine-sam,-md

Articles

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Dr. Sam on Sequencing Tucatinib and Trastuzumab Deruxtecan in HER2+ Breast Cancer

Christine Sam, MD
August 16th 2021

Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.

Read More

Christine Sam, MD

Dr. Sam on Therapeutic Developments in Metastatic HER2+ Breast Cancer

Christine Sam, MD
August 12th 2021

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

Read More

Christine Sam, MD, assistant member, Department of Individualized Cancer Management/Senior Adult Oncology Program, Moffitt Cancer Center

Dr. Sam on Managing ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

Christine Sam, MD
August 3rd 2021

Christine Sam, MD, shares strategies to manage interstitial lung disease experienced with fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Read More

Dr. Sam on the Importance of Performing Geriatric Assessments During the COVID-19 Pandemic

Dr. Sam on the Importance of Performing Geriatric Assessments During the COVID-19 Pandemic

Christine Sam, MD
September 30th 2020

Christine Sam, MD, discusses the importance of ​performing geriatric assessments during the coronavirus disease 2019 pandemic​.

Read More

Dr. Sam on Mitigating Risk of COVID-19 in Elderly Patients With Cancer

Dr. Sam on Mitigating Risk of COVID-19 in Elderly Patients With Cancer

Christine Sam, MD
August 19th 2020

Christine Sam, MD, discusses strategies to mitigate the risk of the coronavirus disease 2019 in elderly patients with cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need